analysis

CORONA Remedies Ltd.

NSE: CORONA

BSE: 544644

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,022.80+43.4 (+2.19%)

9 Jul, 3:30 PM

Overview Analysis

Statements Technicals Forecast Peers Resources News

Summary Recommendation

A summary recommendation on the stock based on our classification and scoring techniques along with analyst recommendations.

StyleBox^TMWhat is StyleBox?

Market angel

The stock is high on quality and momentum, not the cheapest but still favoured. A potential buy.

Detail >

QVM scoreWhat is QVM score?

61.6 / 100

The stock has moderate QVM score relative to other stocks in the market. Neutral.

Analyst ratingWhat is Analyst rating?

No active sell-side coverage. Recommendations not available.

Technical indicatorsSee all >

65 %

CORONA Remedies Ltd. on 1D timeframe is bullish for 15 out of 23 technical oscillators and moving averages.

Ratios and Statistics

A look at some key ratios and statistics for the stock. Change tabs to find the relevant ratios. Click on chart icon to view historical analysis of a particular ratio.

	2025 Dec 31	2026 Jan 31	2026 Feb 28	2026 Mar 31	2026 Apr 30	2026 May 31	2026 Jun 30	2026 Jul 09
Multiples
P/E (TTM)	56.70	51.70	56.54	55.54	61.75	55.32	65.04	65.40
P/B (latest)	13.96	13.72	14.69	14.43	16.04	13.71	16.12	16.21
P/S (TTM)	7.08	6.97	7.21	7.08	7.87	7.30	8.58	8.63
CAPE (3Y)	-	-	-	-	-	72.28	84.98	85.44
CAPE (5Y)	-	-	-	-	-	-	-	-
P/E (1Y Forward)	-	-	-	-	-	-	-	-
P/S (1Y Forward)	-	-	-	-	-	-	-	-
Yields (%)
Book to Market	0.07	0.07	0.07	0.07	0.06	0.07	0.06	0.06
Earnings yield	1.76%	1.93%	1.77%	1.80%	1.62%	1.81%	1.54%	1.53%
Operating CF yield	2.18%	2.16%	2.01%	2.05%	1.84%	2.24%	1.90%	1.89%
FCFE yield	-	-	-	-	-	1.30%	1.10%	1.10%
FCFF yield	-	-	-	-	-	0.58%	0.50%	0.50%

Historical Performance

Performance with respect to benchmark. Prices are adjusted for splits, bonus and rights issue.

Show dividend adjusted performance

NIFTY50

NIFTYPHARMA

Add benchmark

Note: Prices are adjusted for splits, bonus and rights issue.

Showing:

Performance summary

	CORONA	NIFTY50	NIFTYPHARMA

Start Period	15 Dec 2025	15 Dec 2025	15 Dec 2025
End Period	09 Jul 2026	09 Jul 2026	09 Jul 2026
Cumulative Return	40.69%	-7.93%	12.93%
CAGR	83.64%	-13.68%	24.17%
Volatility (ann.)	34.42%	16.24%	15.47%
Max Drawdown	-9.9%	-15.18%	-7.52%
RoMaD	8.45%	-0.9%	3.21%
Sharpe	1.87	-1.09	1.26
Sortino	2.85	-1.43	2.0
Sortino/√2	2.02	-1.01	1.41

Style Analysis

Learn more about stock scores

Scores on value, momentum and quality parameters. Change tabs to compare across market, sector, industry.

Value score

14.1 / 100

↓

CORONA Remedies Ltd. is overvalued relative to other stocks in the market

What is Value score?

Momentum score

69.5 / 100

–

CORONA Remedies Ltd. has moderate momentum relative to other stocks in the market

What is Momentum score?

Quality score

89.2 / 100

↑

CORONA Remedies Ltd. has high quality relative to other stocks in the market

What is Quality score?

QVM score

61.6 / 100

–

CORONA Remedies Ltd. has moderate QVM score with respect to other stocks in the market

What is QVM score?

Scorecard

How to read Scorecard?

A comprehensive scorecard to compare CORONA Remedies Ltd. on all metrics with other stocks. Access both rank and scores.

	Value	Market (All Stocks in NSE)	Sector (Healthcare)	Industry Group (Pharmaceuticals & Biotechnology)	Industry (Pharmaceuticals)
Size and Listing
Days since Listing	206.00
Enterprise value	12,226 Cr
Issue Price	1,062.00
Listing Price	1,452.00
Market Cap	12,106 Cr
Liquidity
Avg daily turnover 1M	14 Cr
Avg daily volume 1M	74,797
Avg daily turnover 3M	10 Cr
Avg daily volume 3M	57,542
Bid Ask Spread	1.52%
Delivery Percentage	47.03%
Volume surge ratio	1.35
Ownership
DII Holding %	6.93%
QoQ change DII holding %	0.21%
FII Holding %	2.25%
QoQ change FII holding %	0.41%
QoQ change Gov holding %	0.00%
Promoter holding %	69.00%
QoQ change Promoter holding %	0.00%
Promoter pledged %	0.00%
Retail Holding %	20.97%
QoQ change Retail holding %	-0.64%

Checklist

What is Checklist?

Analyse how the stock fares on some investment checklists created by legendary investors and gurus. Also, build your own custom checklist.

O'Shaughnessy Tiny Titans

Benjamin Graham's Value

Piotroski F-Score

Dreman contrarian value

Peter Lynch Growth/Value

O'Shaugnessy Value

Templeton Growth/Value

Warren Buffet’s Consistent Compounders

John Neff’s contrarian value

Richard Driehaus Momentum Strategy

O'Shaughnessy Tiny Titans

Created by the famous investor James O'Shaugnessy, this screen/checklist aims to find out small-cap stocks with significant growth potential. We look for companies with market capitalization between Rs 500 cr and Rs 1500 cr that are reasonable valued and are in the top 25 percentile momentum as measured by Momentum score.

20.0 / 100

CORONA Remedies Ltd. passes 1 out of 5 of this checklist's rules

Hits

Market Cap is greater than ₹500 crore

Misses

Market Cap is less than ₹1500 crore

PS TTM is less than 1

One Year Rel Return is greater than 0%

Stock is in top 25.0 percentile, sorted by Price Momentum score in descending order

Frequently Asked Questions

What is the PB ratio of CORONA Remedies Ltd.?

The Price-to-Book (PB) ratio of CORONA Remedies Ltd. is 16.21. It compares the stock's market price to its book value per share.

What is the EV/EBITDA of CORONA Remedies Ltd.?

The EV/EBITDA of CORONA Remedies Ltd. is 41.67. This ratio is used to assess the overall value of a company relative to its earnings before interest, taxes, depreciation and amortisation.

What is the debt-to-equity ratio of CORONA Remedies Ltd.?

The debt-to-equity (D/E) ratio of CORONA Remedies Ltd. is 0.22. The interest coverage ratio stands at 36.67x, reflecting the company's capacity to service its debt from operating earnings. A lower D/E ratio generally indicates a more financially stable company with less leverage.

What is the promoter holding in CORONA Remedies Ltd.?

Promoters hold 69.00% of CORONA Remedies Ltd. shares as per the latest quarterly shareholding disclosure.

What is the operating profit margin of CORONA Remedies Ltd.?

The operating profit margin of CORONA Remedies Ltd. is 18.21%, reflecting how much profit the company earns from its core operations relative to revenue.

What is the net profit margin of CORONA Remedies Ltd.?

The net profit margin of CORONA Remedies Ltd. is 13.19%, indicating the percentage of revenue that remains as profit after all expenses.

What is the Sharpely score for CORONA Remedies Ltd.?

On Sharpely's proprietary scoring system, CORONA Remedies Ltd. has a Quality Score of 89.2/100, Value Score of 13.8/100 and Price Momentum Score of 68.8/100, with an overall QVM Score of 61.6/100. The quality rating is high, value is low and price momentum is moderate. Visit the Scorecard and Checklist sections on the Analysis tab for a full breakdown.